Danaher Corporation (NYSE: DHR) reported second-quarter revenue of $6.3 billion. Adjusted earnings per share reached $1.94, surpassing analyst expectations. Net earnings increased 60% year-over-year.
The Life Sciences division performed strongly as bioprocessing orders grew by mid-teens. Danaher raised its 2026 full-year adjusted EPS guidance to a range of $8.45 to $8.60.
Shares fell approximately 9% in pre-market trading despite the positive quarterly results. Investors focused on third-quarter core revenue growth guidance of 2.0% to 3.0%. This outlook overshadowed the earnings beat and raised annual forecast. The reaction reflects broader market concerns regarding future growth in the life sciences and diagnostics sectors.